-
Mashup Score: 3Loader - 14 hour(s) ago
We have noticed an unusual activity from your IP 199.16.157.180 and blocked access to this
Source: CheckRare.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1The SUDEP Communication Gap - 14 hour(s) ago
Judith Luker discusses the sudden unexpected death in epilepsy communication gap and the importance of physician-patient conversations.
Source: CheckRare.comCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 1Trofinetide for the Treatment of Rett Syndrome - 14 hour(s) ago
Ponni Subbiah, MD, MPH, Senior Vice President Global Head of Medical Affairs and Chief Medical Officer, Acadia Pharmaceuticals, discusses trofinetide for the treatment of Rett syndrome.
Source: CheckRare.comCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 0
Dr. Varshavsky-Yanovsky discusses the safety of elranatamab in Black or African-American patients with multiple myeloma.
Source: CheckRare.comCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 0Loader - 16 hour(s) ago
We have noticed an unusual activity from your IP 199.16.157.180 and blocked access to this
Source: CheckRare.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Enzyme Replacement Therapy In MPS IVA Patients - 22 hour(s) ago
Barbara Burton, MD, Northwestern University, discusses enzyme replacement therapy in patients with mucopolysaccharidosis (MPS) IVA.
Source: CheckRare.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Loader - 2 day(s) ago
We have noticed an unusual activity from your IP 199.16.157.180 and blocked access to this
Source: CheckRare.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Advances in Sickle Cell Disease - 3 day(s) ago
Dr. Smith-Whitley, pediatric hematologist at the Children’s Hospital of Philadelphia, discusses the advances in sickle cell disease.
Source: CheckRare.comCategories: General Medicine News, Rare DiseaseTweet
-
Mashup Score: 2
For hematologic malignancy (HM) patients admitted to the ICU, survival is 49 percent at seven days and 21 percent at 12 months.
Source: CheckRare.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Incremental cost-effectiveness ratios were $126,000 and $281,000 per QALY for two simulation models from a societal perspective.
Source: CheckRare.comCategories: General Medicine News, Rare DiseaseTweet
Mathias Schmidt, PhD, President and Chief Executive Officer of JCR USA, describes their current clinical trials for patients with mucopolysaccharidosis #MPS I and II #CheckRare #RareDisease https://t.co/9onF5FlegI